Page last updated: 2024-09-04

lonafarnib and cytarabine

lonafarnib has been researched along with cytarabine in 2 studies

Compound Research Comparison

Studies
(lonafarnib)
Trials
(lonafarnib)
Recent Studies (post-2010)
(lonafarnib)
Studies
(cytarabine)
Trials
(cytarabine)
Recent Studies (post-2010) (cytarabine)
224349015,4872,4243,188

Protein Interaction Comparison

ProteinTaxonomylonafarnib (IC50)cytarabine (IC50)
nuclear receptor coactivator 3 isoform aHomo sapiens (human)7.533
E3 ubiquitin-protein ligase Mdm2Homo sapiens (human)0.02

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T1
Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L1

Other Studies

2 other study(ies) available for lonafarnib and cytarabine

ArticleYear
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:3

    Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured

2003
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
    Leukemia, 2005, Volume: 19, Issue:7

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin

2005